SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among US. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis

American Journal of Perinatology

Volumn 34, Issue 1, 2017, Pages 51-61

  Anderson, Evan J ^a   Krilov, Leonard R ^b   DeVincenzo, John P ^c   Checchia, Paul A ^d   Halasa, Natasha ^e   Simões, Eric A F ^f   Domachowske, Joseph B ^g   Forbes, Michael L ^h   Pannaraj, Pia S ⁱ   McBride, Scott J ^j   McLaurin, Kimmie K ^k   Kumar, Veena R ^k   Ambrose, Christopher S ^k  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f University of Colorado Denver and Children s Hospital Colorado   (United States)

^g State University of New York Upstate Medical University: College of Medicine   (United States)

^h AKRON CHILDREN'S HOSPITAL   (United States)

ⁱ CHILDREN S HOSPITAL LOS ANGELES   (United States)

^j UNITED BIOSOURCE CORPORATION   (United States)

^k ASTRAZENECA   (United Kingdom)

more..

Author keywords

bronchiolitis; hospital charges; hospitalization; immunoprophylaxis; infant; palivizumab; preterm; RSV

Indexed keywords

ARTICLE; ARTIFICIAL VENTILATION; CHILD DEATH; COHORT ANALYSIS; COMMUNITY ACQUIRED INFECTION; GESTATIONAL AGE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HOSPITALIZED INFANT; HUMAN; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTPATIENT CARE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; UNITED STATES; AMBULATORY CARE; ECONOMICS; FEMALE; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; MALE; NEWBORN; PEDIATRIC INTENSIVE CARE UNIT; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ANTIVIRUS AGENT; PALIVIZUMAB;

AMBULATORY CARE; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GESTATIONAL AGE; HEALTH CARE COSTS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, PEDIATRIC; MALE; PALIVIZUMAB; RESPIRATION, ARTIFICIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; UNITED STATES;

EID: 85007238799     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0036-1584147     Document Type: Article

References (29)

1. Simões E. A. Respiratory syncytial virus infection. Lancet: 1999; 354 9181 847 852
2. Hall C. B., Hall W. Principles and Practice of Infectious Diseases. 4th ed. New York Churchill Livingstone: 1995
3. Jain S., Williams D. J., Arnold S. R., et al. CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med: 2015; 372 9 835 845
4. Boyce T. G., Mellen B. G., Mitchel E. F. Jr, Wright P. F., Griffin M. R. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr: 2000; 137 6 865 870
5. Langley G. F., Anderson L. J. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J: 2011; 30 6 510 517
6. Stevens T. P., Sinkin R. A., Hall C. B., Maniscalco W. M., McConnochie K. M. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med: 2000; 154 1 55 61
7. DeVincenzo J. P., McClure M. W., Symons J. A., et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med: 2015; 373 21 2048 2058
8. DeVincenzo J. P., Whitley R. J., Mackman R. L., et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med: 2014; 371 8 711 722
9. Simões E. A., DeVincenzo J. P., Boeckh M., et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis: 2015; 211 01 S1 S20
10. Blanken M. O., Rovers M. M., Molenaar J. M., et al. Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med: 2013; 368 19 1791 1799
11. Feltes T. F., Cabalka A. K., Meissner H. C., et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr: 2003; 143 4 532 540
12. IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics: 1998; 102 3 531 537
13. American Academy of Pediatrics Respiratory syncytial virus. In: Pickering L. K., Baker C. J., Kimberlin D. W., Long S. S. eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL American Academy of Pediatrics: 2012; 609 617
14. American Academy of Pediatrics Committee on Infectious Diseases and Bronchiolitis Guidelines Committee Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics: 2014; 134 2 415 420
15. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics: 1998; 102 5 1211 1216
16. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics: 2003; 112 6 Pt 1 1442 1446
17. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis Diagnosis and management of bronchiolitis. Pediatrics: 2006; 118 4 1774 1793
18. American Academy of Pediatrics Committee on Infectious Diseases Policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics: 2009; 124 6 1694 1701
19. Ambrose C. S., Anderson E. J., Simões E. A., et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J: 2014; 33 6 576 582
20. Helfrich A. M., Nylund C. M., Eberly M. D., Eide M. B., Stagliano D. R. Healthy late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization. Early Hum Dev: 2015; 91 9 541 546
21. Winterstein A. G., Knox C. A., Kubilis P., Hampp C. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study. JAMA Pediatr: 2013; 167 12 1118 1124
22. Centers for Disease Control and Prevention Natality public-use data 2007-2014, on CDC WONDER Online Database. Available at: http://wonder.cdc.gov/natality-current.html. Accessed January 15, 2016
23. Joffe S., Escobar G. J., Black S. B., Armstrong M. A., Lieu T. A. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics: 1999; 104 (4 Pt 1): 894 899
24. Carbonell-Estrany X., Quero J.; IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J: 2001; 20 9 874 879
25. Cilla G., Sarasua A., Montes M., et al. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect: 2006; 134 3 506 513
26. Figueras-Aloy J., Carbonell-Estrany X., Quero-Jiménez J., et al. IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J: 2008; 27 9 788 793
27. Greenbaum A. H., Chen J., Reed C., et al. Hospitalizations for severe lower respiratory tract infections. Pediatrics: 2014; 134 3 546 554
28. Lanari M., Giovannini M., Giuffré L., et al. Investigators R.A.D.A.R. Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol: 2002; 33 6 458 465
29. Law B. J., Langley J. M., Allen U., et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J: 2004; 23 9 806 814